Garry Neil, M.D.
Garry Neil, M.D., Dr. Neil joined Medgenics in September 2013 the Cheif Scientific Officer. He was a Partner at Apple Tree Partners, a life sciences private equity fund. Prior to joining Apple Tree Partners in 2012, he was Corporate VP of Science & Technology at Johnson & Johnson, and Group President, Johnson & Johnson Pharmaceutical Research and Development. Prior to joining Johnson & Johnson in 2002, he held senior positions at Astra Merck, AstraZeneca, and EMD Pharmaceuticals. Under his leadership a number of important new medicines for the treatment of cancer, infectious disease, metabolic diseases, women’s health, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases gained initial or expanded approvals.
Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. He completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He held faculty positions at the Ludwig Institute for Cancer Research, the University of Iowa and the University of Pennsylvania (adjunct).
He serves on the Boards of Reagan Udall Foundation and the Foundation for the U.S. National Institutes of Health (NIH), and is a past member of the Science Management Review Board of the NIH. He is past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA Foundation Board and the founding Chairman of Transcelerate Biopharmaceuticals, inc.